期刊文献+

LncRNA FGD5-AS1通过miR-873-5p/GTPBP4轴促进肝细胞癌发展的研究 被引量:3

The research of LncRNA FGD5-AS1 promotes hepatocellular carcinoma progression through miR-873-5p/GTPBP4 axis
下载PDF
导出
摘要 目的探讨长链非编码RNA(lncRNA)FGD5-AS1对肝细胞癌(HCC)发展的调控机制。方法通过RT-qPCR检测FGD5-AS1在肝癌组织和肝癌细胞系中的表达水平。采用CCK-8、EdU、流式细胞术、细胞划痕实验和Transwell实验检测FGD5-AS1对HCC细胞增殖、凋亡、迁移和侵袭中的作用。运用双荧光素酶报告和RNA下拉实验探明FGD5-AS1、miR-873-5p和GTPBP4之间的相互作用。结果FGD5-AS1在肝癌组织和细胞中表达上调。FGD5-AS1表达下调可抑制HCC细胞的增殖、迁移和侵袭,并诱导其凋亡。FGD5-AS1直接与miR-873-5p结合,并竞争性抑制其表达,以提高HCC细胞中促癌基因GTPBP4的表达水平。FGD5-AS1的作用是由miR-873-5p/GTPBP4轴介导的。结论FGD5-AS1可通过调控miR-873-5p/GTPBP4轴从而促进HCC细胞的增殖、迁移和侵袭,并抑制其凋亡。 Objective To explore the regulatory mechanism of the long noncoding FGD5-AS1(LncRNA FGD5-AS1)on hepatocellular carcinoma(HCC)progression.Methods The expression level of FGD5-AS1 was measured in tumor tissues and cell lines by RT-qPCR.CCK-8,EdU,flow cytometry,wound healing and transwell chamber assays were performed to investigate the role of FGD5-AS1 in HCC cell proliferation,apoptosis,migration and invasion in vitro.At the molecular level,dual luciferase reporter and RNA pull down assays were performed to identify the interaction among FGD5-AS1,miR-873-5p and GTPBP4.Results FGD5-AS1 was upregulated in HCC tissues and cells.Moreover,FGD5-AS1 knockdown suppressed HCC cell proliferation,migration and invasion,and induced apoptosis in vitro.Mechanistically,FGD5-AS1 directly bound to miR-873-5p and competitively inhibit its expression to increase the expression level of GTPBP4 in HCC cells.Finally,our findings indicated that the role of FGD5-AS1 was mediated by miR-873-5p GTPBP4 axis.Conclusion FGD5-AS1 promotes the proliferation,migration and invasion of HCC cells and inhibits apoptosis by regulating the miR-873-5p/GTPBP4 axis.
作者 章诺贝 黄神安 沈浩 陈新 Zhang Nuobei;Huang Shen′an;Shen Hao;Chen Xin(Dept of Gastroenterology,The Second Affiliated Hospital of Nanchang University,Nanchang 330006;Dept of Nuclear Medicine,The Second Affiliated Hospital of Nanchang University,Nanchang 330006)
出处 《安徽医科大学学报》 CAS 北大核心 2022年第2期240-247,共8页 Acta Universitatis Medicinalis Anhui
基金 国家自然科学基金(编号:81760427) 江西省自然科学基金(编号:20202BABL206094、20202BABL216037) 江西省卫生健康委科技计划(编号:20201037、202110042)。
关键词 肝细胞癌 LncRNA FGD5-AS1 miR-873-5p GTPBP4 hepatocellular carcinoma LncRNA FGD5-AS1 miR-873-5p GTPBP4
  • 相关文献

参考文献1

二级参考文献115

  • 1Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, MinerJN, Mumberg D, Ziegelbauer K, Scholz A. Allosteric MEK1/2inhibitor refametinib (BAY 86-9766) in combination with sorafenibexhibits antitumor activity in preclinical murine and rat models ofhepatocellular carcinoma. Neoplasia 2013; 15: 1161-1171 [PMID:24204195 DOI: 10.1593/neo.13812].
  • 2Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT,Liu CY, Chen KF, Shiau CW. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation inhepatocellular carcinoma. Neoplasia 2014; 16: 595-605 [PMID:25047655 DOI: 10.1016/j.neo.2014.06.005].
  • 3Xia H, Ooi LL, Hui KM. MicroRNA-216a/217-induced epithelialmesenchymaltransition targets PTEN and SMAD7 to promotedrug resistance and recurrence of liver cancer. Hepatology 2013;58: 629-641 [PMID: 23471579 DOI: 10.1002/hep.26369].
  • 4El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiologyand molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061].
  • 5Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, SekiE, Karin M. p38α inhibits liver fibrogenesis and consequenthepatocarcinogenesis by curtailing accumulation of reactiveoxygen species. Cancer Res 2013; 73: 215-224 [PMID: 23271722DOI: 10.1158/0008-5472.can-12-1602].
  • 6Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, Gao Y, ZhangS, Lu Z, Ye L, Zhang X. Hepatitis B virus X protein inhibitstumor suppressor miR-205 through inducing hypermethylation ofmiR-205 promoter to enhance carcinogenesis. Neoplasia 2013; 15:1282-1291 [PMID: 24339740 DOI: 10.1593/neo.131362].
  • 7Qi LN, Bai T, Chen ZS, Wu FX, Chen YY, De Xiang B, PengT, Han ZG, Li LQ. The p53 mutation spectrum in hepatocellularcarcinoma from Guangxi, China : role of chronic hepatitis B virusinfection and aflatoxin B1 exposure. Liver Int 2015; 35: 999-1009[PMID: 24461059 DOI: 10.1111/liv.12460].
  • 8Aravalli RN, Cressman EN, Steer CJ. Cellular and molecularmechanisms of hepatocellular carcinoma: an update. ArchToxicol 2013; 87: 227-247 [PMID: 23007558 DOI: 10.1007/s00204-012-0931-2].
  • 9Shin JW, Chung YH. Molecular targeted therapy for hepatocellularcarcinoma: current and future. World J Gastroenterol 2013; 19:6144-6155 [PMID: 24115810 DOI: 10.3748/wjg.v19.i37.6144].
  • 10Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D, Liu L. Thelong intergenic noncoding RNA UFC1, a target of MicroRNA 34a,interacts with the mRNA stabilizing protein HuR to increase levelsof β-catenin in HCC cells. Gastroenterology 2015; 148: 415-426.e18 [PMID: 25449213 DOI: 10.1053/j.gastro.2014.10.012].

共引文献18

同被引文献40

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部